Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending July 15, 2018
Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052
CAVEAT shows venetoclax plus chemo appropriate for older, fit AML patients , Wei AH et al. EHA Congress, Abstract S1564.
Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.
Patients who develop AML may have detectable mutations years earlier, Desai P et al. Nat Med. 2018;24:1015-23.
Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.
Must reads for theWeek ending July 8, 2018
ALL patients' liver toxicities linked to antibiotics, other therapies, Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.
Thrombocytopenia in pregnancy raises risk of complications, Reese J et al. N Engl J Med. 2018;379:32-43.
Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.
PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Hydroxyurea tolerated well in sickle cell patients, Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.
Must reads for theWeek ending July 1, 2018
Lenalidomide-refractory MM responds to triple therapy, Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).
Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.
Relapsed CLL responds to rapid venetoclax dose-escalation, Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357
Doubling of deaths in hospice care over 5-year span, Teno JM et al. JAMA. 2018 Jun 25. doi: 10.1001/jama.2018.8981.
What standard should be used for clinical trials of checkpoint inhibitors?, Gyawali B et al. JAMA Network Open. 2018 June 22. doi: 10.1001/jamanetworkopen.2018.0416
Must reads for theWeek ending June 24, 2018
RCC recurrence may be predicted by protein activation, Ichiyanagi O et al. Clin Genitourin Cancer. 2018 June 8. doi: 10.1016/j.clgc.2018.06.002.
Policy statement on access to opioid medications, Statement on Opioid Use in Patients with Hematologic Diseases and Disorders, American Society of Hematology
FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label (Drugs@FDA)
FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information (Drugs@FDA)
Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.
Must reads for theWeek ending June 17, 2018
Oncologists file suit challenging Part B payment reductions, May 30 letter to HHS Secretary Alex Azar alerting him to the legal action, which was filed on May 31.
One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.
Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.
Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.
CLL gets to MRD with combo therapy, Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.